Opera Limited, together with its subsidiaries, provides mobile and PC web browsers. It operates in two segments, Browser and News, and Other. The company offers mobile browser products, such as Opera Mini, Opera for Android and iOS, Opera GX Mobile, and Opera Touch; PC browsers, including Opera for Computers and Opera GX; and Opera News, an AI-powered personalized news discovery and aggregation service. It also provides browser-based cashback rewards under the Dify brand name; owns GameMaker Studio, a 2D gaming development platform; and GXC, a gaming portal. In addition, the company operates online marketing platforms, including Opera Ads, an online advertising platform; and Opera Ads Manager, designs to create, manage, and report on digital advertising campaigns in one place allowing advertisers to reach customers. It operates in Ireland, Singapore, Russia, and internationally. The company was founded in 1995 and is headquartered in Oslo, Norway. Opera Limited is a subsidiary of Kunlun Tech Limited.

Opera Limited

Perfect Corp. provides SaaS artificial intelligence and augmented reality beauty and fashion tech business solutions. The company offers AR makeup virtual try-on, YouCam tutorial, AI foundation shade finder and matcher, AI virtual background changer, AI skin analysis, AI face analyzer, AI face reshape simulator, AI personality finder, in-store barcode try-on, AI virtual hair color try-on, AR hairstyle virtual try-on, AI beard dye and beard style virtual try-on, hat and headband virtual try-on, AI-powered virtual try-on for glasses, virtual try-on for nails, AR watch virtual try-on, AR ring virtual try-on, AR bracelet virtual try-on, and AR earring virtual try-on solutions and services. It also provides YouCam makeup, YouCam perfect, YouCam video, YouCam cut, YouCam nails, and YouCam fun apps. The company was founded in 2015 and is based in New Taipei City, Taiwan.

Perfect Corp.

John Marshall Bancorp, Inc. operates as the bank holding company for John Marshall Bank that provides banking products and financial services. The company accepts checking, demand, NOW, savings, and money market accounts, as well as certificates of deposit. It offers commercial, construction and development, commercial term, mortgage, commercial real estate, industrial other commercial lines of credit; debit and credit cards; and treasury and cash management, investment, business and personal insurance, remote deposit capture, deposit sweep and online and mobile banking services. The company serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals. It operates eight full-service branches in Alexandria, Reston, Arlington, Washington, Loudoun, Prince William, Rockville, and Tysons, as well as a loan production office in Arlington, Virginia. The company was founded in 2005 and is headquartered in Reston, Virginia.

John Marshall Bancorp, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics, Inc.

Utz Brands, Inc. operates as a snack food manufacturing company. It offers a range of salty snacks, including potato chips, kettle chips, tortilla chips, pretzels, cheese snacks, veggie snacks, pork skins, pub/party mixes, salsa and queso, ready-to-eat popcorn, and other snacks under the Utz, Zapp's, ON THE BORDER, Golden Flake, Good Health, Boulder Canyon, Hawaiian, TGIF, TORTIYAHS!, and other brand names. The company distributes its products to grocery, mass, club, convenience, drug, and other retailers though direct shipments, distributors, and direct store delivery routes. Utz Brands, Inc. was founded in 1921 and is headquartered in Hanover, Pennsylvania.

Utz Brands, Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals Inc.

Lucid Group, Inc. a technology and automotive company, develops electric vehicle (EV) technologies. The company designs, engineers, and builds electric vehicles, EV powertrains, and battery systems. As of December 31, 2021, it operates twenty retail studios in the United States. Lucid Group, Inc. was founded in 2007 and is headquartered in Newark, California.

Lucid Group, Inc.

As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Atlantic International Corp.

Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States, the United Kingdom, the rest of Europe, and Canada. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It also participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in St. Louis, Missouri.

Stifel Financial Corp.

American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.

American Electric Power Company, Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

Blackbaud, Inc. provides cloud software solutions to higher education institutions, K12 schools, healthcare organizations, faith communities, arts and cultural organizations, foundations, companies, and individual change agents in the United States and internationally. The company offers fundraising and relationship management solutions, such as Blackbaud Raiser's Edge NXT and Blackbaud CRM, Blackbaud eTapestry, Blackbaud TeamRaiser, JustGiving, and Blackbaud Guided Fundraising and Blackbaud Volunteer Network Fundraising; marketing and engagement solutions, including Blackbaud Luminate Online, Blackbaud Online Express, and Blackbaud School Website System; and financial management solutions comprising Blackbaud Financial Edge NXT, Blackbaud Tuition Management, and Blackbaud Financial Aid Management. It also provides grant and award management solutions, consisting of Blackbaud Grantmaking and Blackbaud Award Management; organizational and program management, such as Blackbaud Student Information System, Blackbaud Learning Management System, Blackbaud Enrollment Management System, Blackbaud Altru, and Blackbaud Church Management; social responsibility solutions, which includes YourCause GrantsConnect and YourCause CSRconnect; Blackbaud Merchant Services and Blackbaud Purchase Cards payment services; and Blackbaud's Intelligence for Good solutions, as well as donor acquisition, prospect research, data enrichment, and benchmarking and performance management solutions and services. It sells its solutions and related services through its direct sales force. Blackbaud, Inc. was founded in 1981 and is headquartered in Charleston, South Carolina.

Blackbaud, Inc.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Company

Accel Entertainment, Inc., together with its subsidiaries, operates as a distributed gaming operator in the United States. It is involved in the installation, maintenance, and operation of gaming terminals; redemption devices that disburse winnings and contain automated teller machine (ATM) functionality; and other amusement devices in authorized non-casino locations, such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The company also provides licensed establishment partners gaming solutions that appeal to players who patronize those businesses. In addition, it operates stand-alone ATMs in gaming and non-gaming locations, as well as amusement devices, including jukeboxes, dartboards, pool tables, pinball machines, and other related entertainment equipment. As of December 31, 2021, the company operated 13,639 video gaming terminals across 2,584 locations in Illinois. Accel Entertainment, Inc. is headquartered in Burr Ridge, Illinois.

Accel Entertainment, Inc.

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

Marathon Digital Holdings, Inc.

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

Nutex Health, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals, Inc.

Discover the most dynamic companies of the U.S. market, driving exceptional revenue growth across industries. This curated list highlights market leaders and emerging innovators achieving rapid expansion through cutting-edge technology, strategic execution, and customer-driven innovation.

From disruptive startups to established corporations, these high-growth organizations are redefining their sectors and capturing investor attention with their sustained financial momentum and scalable business models.

#	Company	Industry	Price	Market Cap	P/E	Dividend	DCF	Score	Value	Profit	Growth	Health
1	Opera Limited OPRA NASDAQ NO	Internet Conten…	$13.61 -0.81 (2.99%)	$1.22 B	17.11	$0.78	-	0 / 100	- / 100	- / 100	- / 100	- / 100
2	Perfect Corp. PERF NYSE TW	Software - Appl…	$1.90 -0.19 (-5.44%)	$193.51 M	34.61	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
3	John Marshall Bancorp, Inc. JMSB NASDAQ US	Banks - Regiona…	$18.92 -0.09 (0.00%)	$269.02 M	0.00	$0.30	-	0 / 100	- / 100	- / 100	- / 100	- / 100
4	TG Therapeutics, Inc. TGTX NASDAQ US	Biotechnology	$33.81 0.12 (2.49%)	$5.36 B	87.35	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
5	Utz Brands, Inc. UTZ NYSE US	Packaged Foods	$10.11 -0.29 (-2.47%)	$864.20 M	182.03	$0.24	-	0 / 100	- / 100	- / 100	- / 100	- / 100
6	CorMedix Inc. CRMD NASDAQ US	Biotechnology	$11.42 -0.12 (23.01%)	$852.42 M	16.36	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
7	Aurinia Pharmaceuticals Inc. AUPH NASDAQ CA	Biotechnology	$14.27 1.10 (-5.42%)	$1.88 B	18.71	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
8	Lucid Group, Inc. LCID NASDAQ US	Auto - Manufact…	$16.36 -0.28 (2.00%)	$5.03 B	-2.81	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
9	Atlantic International Corp. ATLN NASDAQ US	Medical - Diagn…	$2.61 -0.02 (NaN%)	$163.01 M	-1.14	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
10	Stifel Financial Corp. SF NYSE US	Financial - Cap…	$119.43 0.30 (0.03%)	$12.18 B	0.06	$1.80	-	0 / 100	- / 100	- / 100	- / 100	- / 100
11	American Electric Power Compan... AEP NASDAQ US	Regulated Elect…	$120.30 0.38 (0.04%)	$64.39 B	16.43	$3.72	-	0 / 100	- / 100	- / 100	- / 100	- / 100
12	Beam Therapeutics Inc. BEAM NASDAQ US	Biotechnology	$22.74 -1.51 (-3.33%)	$2.30 B	-6.00	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
13	Blackbaud, Inc. BLKB NASDAQ US	Software - Appl…	$62.06 -1.82 (0.53%)	$3.01 B	-12.12	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
14	Geron Corporation GERN NASDAQ US	Biotechnology	$1.15 -0.05 (-7.43%)	$733.72 M	-10.67	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
15	Eton Pharmaceuticals, Inc. ETON NASDAQ US	Biotechnology	$18.45 0.49 (-1.42%)	$494.78 M	-92.84	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
16	STAAR Surgical Company STAA NASDAQ US	Medical - Instr…	$25.28 0.02 (-2.11%)	$1.25 B	-0.00	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
17	Accel Entertainment, Inc. ACEL NYSE US	Gambling, Resor…	$9.93 -0.06 (-0.10%)	$837.04 M	28.66	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
18	Marathon Digital Holdings, Inc... MARA NASDAQ US	Financial - Cap…	$16.62 -1.19 (2.03%)	$6.16 B	0.00	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
19	Nutex Health, Inc. NUTX NASDAQ US	Medical - Healt…	$126.71 -5.00 (-3.81%)	$703.89 M	3.86	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
20	Apellis Pharmaceuticals, Inc. APLS NASDAQ US	Biotechnology	$20.47 -0.22 (-0.29%)	$2.59 B	63.40	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100

Fastest Growing Companies By Revenue